Trial Profile
A One Week Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study With Creon 40,000 MMS in Subjects With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis, Followed by an Open-Label Long-Term Extension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jan 2022
Price :
$35
*
At a glance
- Drugs Pancrelipase (Primary)
- Indications Exocrine pancreatic insufficiency
- Focus Registrational; Therapeutic Use
- Sponsors Abbott Healthcare Products
- 13 Mar 2018 New trial record